Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine.

The mechanism of 3,4-methylenedioxymethamphetamine (MDMA)-induced depletion of brain serotonin (5-hydroxytryptamine, 5-HT) has been proposed to involve the generation of reactive oxygen species. In the present study, quantification of the extracellular concentration of 2,3-dihydroxybenzoic acid (2,3-DHBA) from salicylic acid was used as an index of hydroxyl radical generation. Although both MDMA and D-amphetamine markedly increased the extracellular concentration of dopamine in the striatum, only MDMA increased the extracellular concentration of 2,3-DHBA. Treatment with fluoxetine either 1 h prior to or 4 h following the administration of MDMA reduced the MDMA-induced formation of 2,3-DHBA and also attenuated the MDMA-induced depletion of 5-HT in the striatum. These results are supportive of the view that the MDMA-induced generation of hydroxyl radicals and, ultimately, the long-term depletion of 5-HT, is dependent, in part, on the activation of the 5-HT transporter.

[1]  G. Hanson,et al.  Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. , 1988, The Journal of pharmacology and experimental therapeutics.

[2]  A. Cho,et al.  Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. , 1990, The Journal of pharmacology and experimental therapeutics.

[3]  M. Colado,et al.  In vivo evidence against clomethiazole being neuroprotective against MDMA (‘ecstasy’)-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism , 1999, Neuropharmacology.

[4]  G. C. Wagner,et al.  Methamphetamine-induced neuronal damage: A possible role for free radicals , 1989, Neuropharmacology.

[5]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[6]  G. Hanson,et al.  In Vitro Reactivation of Rat Cortical Tryptophan Hydroxylase Following In Vivo Inactivation by Methylenedioxymethamphetamine , 1989, Journal of neurochemistry.

[7]  D. Nichols,et al.  The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. , 1995, The Journal of pharmacology and experimental therapeutics.

[8]  G. Dryhurst,et al.  7-S-glutathionyl-tryptamine-4,5-dione: a possible aberrant metabolite of serotonin. , 1993, Biochemical pharmacology.

[9]  U. McCann,et al.  Memory impairment in abstinent MDMA ("Ecstasy") users , 1998, Neurology.

[10]  M. Colado,et al.  The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones. , 1995, European journal of pharmacology.

[11]  J. Kehne,et al.  Neurotoxicity of MDMA: Neurochemical Effects , 1990, Annals of the New York Academy of Sciences.

[12]  E. D. De Souza,et al.  3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. , 1987, The Journal of pharmacology and experimental therapeutics.

[13]  L. Steranka,et al.  Effect of cysteine on the persistent depletion of brain monoamines by amphetamine, p-chloroamphetamine and MPTP. , 1987, European journal of pharmacology.

[14]  D E Nichols,et al.  An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. , 1998, Neurotoxicology.

[15]  C. J. Schmidt,et al.  Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. , 1987, Biochemical pharmacology.

[16]  M. Colado,et al.  In vivo evidence for free radical involvement in the degeneration of rat brain 5‐HT following administration of MDMA (‘ecstasy’) and p‐chloroamphetamine but not the degeneration following fenfluramine , 1997, British journal of pharmacology.

[17]  C. Epstein,et al.  Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn‐superoxide dismutase transgenic mice , 1995, Synapse.

[18]  B. Yamamoto,et al.  Mazindol Attenuates the 3,4‐Methylenedioxymethamphetamine‐Induced Formation of Hydroxyl Radicals and Long‐Term Depletion of Serotonin in the Striatum , 1999, Journal of neurochemistry.

[19]  G. Cohen.  Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. , 1987, Advances in neurology.

[20]  G. Battaglia,et al.  Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[21]  G. Gudelsky,et al.  Carrier‐Mediated Release of Serotonin by 3,4‐Methylenedioxymethamphetamine: Implications for Serotonin‐Dopamine Interactions , 1996, Journal of neurochemistry.

[22]  S. Ohnishi,et al.  Central Nervous System Trauma: Research Techniques , 1995 .

[23]  M. P. Johnson,et al.  Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats , 1991, Neuropharmacology.

[24]  G. Hanson,et al.  Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. , 1997, The Journal of pharmacology and experimental therapeutics.

[25]  G. Hanson,et al.  Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat , 1987, Neuropharmacology.

[26]  A. Gardier,et al.  Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: relationship with brain concentrations of fluoxetine and norfluoxetine. , 1994, Life sciences.

[27]  R. Floyd,et al.  Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate hydroxylation products. , 1984, Journal of biochemical and biophysical methods.

[28]  B. Yamamoto,et al.  Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. , 1994, European journal of pharmacology.

[29]  J. Cadet,et al.  Invited Review Free radicals and the pathobiology of brain dopamine systems , 1998, Neurochemistry International.

[30]  S. Garattini,et al.  Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain , 1992, Neuropharmacology.

[31]  M. Shankaran,et al.  Effect of 3,4-Methylenedioxymethamphetamine (MDMA) on Hippocampal Dopamine and Serotonin , 1998, Pharmacology Biochemistry and Behavior.

[32]  J. del Río,et al.  MDMA ('Ecstasy') enhances 5-HT1A receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. , 1998, European journal of pharmacology.

[33]  W. Slikker,et al.  Neuropathological evaluation by combined immunohistochemistry and degeneration-specific methods: application to methylenedioxymethamphetamine. , 1988, Neurotoxicology.

[34]  D. Graham.  Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[35]  E. Pehek,et al.  A neurochemical heterogeneity of the rat striatum as measured by in vivo electrochemistry and microdialysis , 1990, Brain Research.

[36]  W. Lovenberg,et al.  In vitro demonstration of dopamine uptake by neostriatal serotonergic neurons of the rat , 1985, Neuroscience Letters.

[37]  M. Colado,et al.  Studies on the role of dopamine in the degeneration of 5‐HT nerve endings in the brain of Dark Agouti rats following 3,4‐methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration , 1999, British journal of pharmacology.

[38]  G. Dryhurst,et al.  Oxidation of serotonin by superoxide radical: implications to neurodegenerative brain disorders. , 1998, Chemical research in toxicology.

[39]  C. J. Schmidt,et al.  Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. , 1987, The Journal of pharmacology and experimental therapeutics.

[40]  G. Hanson,et al.  The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. , 1986, European journal of pharmacology.

[41]  M. Colado,et al.  The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype , 1995, British journal of pharmacology.

[42]  D. Boismenu,et al.  Evaluation of sodium 4-hydroxybenzoate as an hydroxyl radical trap using gas chromatography-mass spectrometry and high-performance liquid chromatography with electrochemical detection. , 1996, Analytical biochemistry.

[43]  F. Wan,et al.  Amphetamine induces hydroxyl radical formation in the striatum of rats. , 1997, Life sciences.

[44]  J. Brodkin,et al.  Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity , 1993, Pharmacology Biochemistry and Behavior.

[45]  R. T. Jackson,et al.  Active [3H]-dopamine uptake by human lymphocytes: correlates with serotonin transporter activity. , 1994, Pharmacology.

[46]  G. Hanson,et al.  Neurochemical basis of neurotoxicity. , 1990, Neurotoxicology.

[47]  L. Seiden,et al.  Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. , 1996, The Journal of pharmacology and experimental therapeutics.

[48]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.